Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2021-06-30 Board/Management Inform…
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Catherine Mackey, Ph.D., to the Board of Directors of Trillium Therapeutics. It focuses on management changes and does not contain financial data, audit information, or detailed report content. The key phrase is 'appoints to its Board of Directors,' which clearly indicates a management or board change announcement. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 5678 characters, which is sufficient for a detailed announcement but does not contain financial statements or report data. Hence, the classification is MANG with high confidence.
2021-06-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the dosing of the first patient in a Phase 1b/2 clinical study by Trillium Therapeutics. It discusses clinical trial details, drug mechanism, and company information. There are no financial statements, regulatory filings, or detailed financial data. It is not an earnings release, annual report, or any form of financial or governance report. It is a corporate announcement about clinical trial progress, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-06-29 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Trillium Therapeutics has joined the Russell 2000 and 3000 indices. It contains no financial statements, no detailed financial data, no management discussion of results, no voting results, no legal proceedings, no capital changes, and no other regulatory or financial report content. It is a corporate announcement about index inclusion, which is a regulatory or general corporate announcement rather than a financial report or meeting material. The document length is 6289 characters, which is sufficient to contain substantive content, but the content is clearly a news announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2021-06-26 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders' and provides detailed voting results for director elections and other shareholder votes. It references the Annual General Meeting (AGM) held on June 8, 2021, and includes specific vote counts and percentages. The content focuses solely on the announcement of voting outcomes rather than the full AGM materials or presentations. The document length is relatively short (2366 characters), and it does not contain financial statements or detailed report content. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-06-09 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notice pursuant to subsection 11.3 of National Instrument 51-102 regarding continuous disclosure obligations. It provides detailed official results of shareholder votes from the Annual General and Special Meeting held on June 8, 2021. The content includes election of directors, appointment of auditors, advisory votes on executive compensation, and frequency of future advisory votes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused solely on voting results, not a full report or presentation.
2021-06-09 English
News release - English.pdf
Regulatory Filings
2021-05-07 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.